CASI制药

CASI NASDAQ
3.150
-0.040
-1.25%
交易中 10:00 08/23 EDT
开盘
3.170
昨收
3.190
最高
3.200
最低
3.150
成交量
1,576
成交均量(3M)
16.79万
52周最高
7.77
52周最低
2.730
换手率
0.00%
市值
2.51亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供CASI制药 CASI股票价格,CASI制药股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development. Its ENMD-2076 is an orally active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. Its Marqibo is a sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate. Its ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. Its EVOMELA is an intravenous formulation of melphalan being investigated by Spectrum in the multiple myeloma transplant setting. Its pipeline also includes 2ME2 (2-methoxyestradial).
展开 >

最近浏览

名称
价格
涨跌幅